Novartis Ag (NVS) EBT (2009 - 2025)

Novartis Ag (NVS) has 15 years of EBT data on file, last reported at $4.5 billion in Q2 2025.

• Quarterly EBT rose 17.96% year-over-year to $4.5 billion in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $20.5 billion (down 99.59% YoY) and the FY2025 annual result came in at $16.4 billion, up 19.88% from the prior year.
• EBT eased to $4.5 billion in Q2 2025 per NVS's latest filing, from $7.0 billion in the prior quarter.
• The five-year high for EBT was $34000.9 billion in Q1 2022, with the low at $927.0 million in Q3 2021.
• Average EBT over 5 years is $2860.3 billion, with a median of $4.6 billion recorded in 2022.
• Year-over-year, EBT soared 3648067.6% in 2022 and tumbled 85.29% in 2023.
• Novartis Ag's EBT stood at $6.0 billion in 2021, then decreased by 20.9% to $4.7 billion in 2022, then climbed by 10.25% to $5.2 billion in 2023, then surged by 34.19% to $7.0 billion in 2024, then tumbled by 34.99% to $4.5 billion in 2025.
• Business Quant data shows NVS's EBT at $4.5 billion in Q2 2025, $7.0 billion in Q4 2024, and $3.8 billion in Q2 2024.